- ICH GCP
- Registre américain des essais cliniques
- Essai clinique NCT07849673
Improving ILD Screening in Patients With RA and SSc Using EHR-Embedded CDS and PRO Tools (ILD-QUI)
This is a quality improvement initiative that aims to find better ways to identify interstitial lung disease (ILD) early in people with rheumatoid arthritis (RA) or systemic sclerosis (SSc). ILD is a serious lung problem that can develop in these conditions but is often missed. The project will test whether tools built into the electronic health record (EHR), including symptom surveys that patients complete on a tablet and alerts that help doctors decide when lung testing is needed, can increase screening rates.
About 16 rheumatology clinics that use the same EHR system will take part. All clinics will eventually use the new tools, but they will start at different times. This allows researchers to compare usual care to the new approach within each clinic.
Adults with RA or SSc who have not previously been diagnosed with ILD and who have not had recent lung testing will be included automatically through their routine clinic visits. The study expects to include about 800 patients in total.
The main question is whether more eligible patients receive recommended ILD screening, which includes either a pulmonary function test or a high-resolution CT scan, within seven days of their clinic visit. The study will also look at how often lung tests are ordered and completed, how often patients report symptoms such as shortness of breath or cough, and whether the alerts lead to real-time clinical decisions.
This project lasts two years and uses information already collected during routine clinical care. No additional procedures or medications are required.
Aperçu de l'étude
Statut
Les conditions
Intervention / Traitement
Description détaillée
Interstitial lung disease (ILD) is a common and serious complication of rheumatoid arthritis (RA) and systemic sclerosis (SSc). Despite guideline recommendations, ILD screening in routine care remains low, and many patients are not evaluated until their lung disease is advanced. This study evaluates a pragmatic, clinic-integrated strategy designed to increase timely ILD screening using tools embedded directly into the electronic health record (EHR).
The project is conducted within community rheumatology practices that share a common EHR platform (NextGen). All participating sites transition from usual care to the intervention, but at different scheduled time points. This stepped-wedge design allows each site to contribute both control-phase and intervention-phase data. Screening is not researcher-initiated; instead, the intervention is designed to support and standardize existing clinical workflows.
The intervention consists of two components implemented at the clinic level. First, patients complete a brief respiratory symptom survey on a tablet at check-in. The questionnaire captures dyspnea and cough severity and is designed to take under two minutes. The results become available to clinicians in real time. Second, EHR-embedded clinical decision support (CDS) prompts appear for clinicians when patients meet predefined criteria based on diagnosis, test history, and symptom scores. These prompts remind clinicians of guideline-recommended ILD screening and facilitate ordering of pulmonary function tests or high-resolution computed tomography when appropriate. Sites also receive training and a structured workflow guide to support implementation.
Because the intervention is deployed within routine clinical care, patients are passively included when they present for appointments and meet study criteria in the EHR. No additional study visits, procedures, or medications are required. Data are collected from the EHR, CDS activity logs, and patient-reported surveys. The study observes ordering and completion of ILD screening tests, provider responses to alerts, symptom patterns, and documentation of new ILD diagnoses. Data are analyzed to compare screening activity before and after the clinic transitions to the intervention, adjusting for time effects and patient and site characteristics.
The study aims to generate practical evidence on whether embedding guideline-aligned CDS and rapid symptom assessments into existing workflows can improve ILD screening for RA and SSc patients in real-world community practice. Findings may help inform broader implementation strategies for early detection of ILD and other pulmonary complications in rheumatology populations.
Type d'étude
Inscription (Estimé)
Phase
- N'est pas applicable
Contacts et emplacements
Coordonnées de l'étude
- Nom: Jeffrey R Curtis, MD, MS, MPH
- Numéro de téléphone: 205-937-0585
- E-mail: jc@fastermedicine.org
Sauvegarde des contacts de l'étude
- Nom: Stephanie S Ford, MS
- Numéro de téléphone: 205-410-8480
- E-mail: sf@fastermedicine.org
Critères de participation
Critère d'éligibilité
Âges éligibles pour étudier
Accepte les volontaires sains
Sexes éligibles pour l'étude
La description
Participants must meet all of the following to be included:
Age ≥ 18 years Diagnosis of rheumatoid arthritis (RA) or systemic sclerosis (SSc) No prior diagnosis of interstitial lung disease (ILD) No high-resolution CT (HRCT) or pulmonary function test (PFT) within the past 24 months
Participants meeting any of the following are excluded:
Confirmed diagnosis of ILD Recent HRCT or PFT within the last 24 months without new symptoms
Plan d'étude
Comment l'étude est-elle conçue ?
Détails de conception
- Objectif principal: La prévention
- Répartition: N / A
- Modèle interventionnel: Affectation séquentielle
- Masquage: Aucun (étiquette ouverte)
Armes et Interventions
Groupe de participants / Bras |
Intervention / Traitement |
|---|---|
|
Expérimental: EHR-Embedded CDS and PRO Tools
This is a quality-improvement, workflow-embedded intervention, the stepped-wedge design evaluates the effect of an active intervention (EHR-embedded CDS + PRO tools). |
This intervention integrates two components directly into routine rheumatology clinic workflows using the shared NextGen electronic health record (EHR). First, patients complete a brief tablet-based respiratory symptom questionnaire at check-in, capturing dyspnea and cough severity in under two minutes. Responses are transmitted instantly into the EHR. Second, the system activates ILD-focused clinical decision support (CDS) prompts for clinicians based on diagnosis, prior testing history, and symptom scores. These prompts recommend guideline-aligned ILD screening and provide structured options for ordering pulmonary function tests or high-resolution chest CT. The CDS also records provider responses and reasons for deferring screening. The intervention is deployed at the site level and is intended to standardize ILD screening behavior, enhance recognition of respiratory symptoms, and support timely clinical action in RA and SSc patients. |
Que mesure l'étude ?
Principaux critères de jugement
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Receipt of ILD Screening
Délai: Within 7 days of the index rheumatology clinic visit
|
Proportion of eligible patients who receive an ILD screening test (high-resolution CT [HRCT] or pulmonary function test [PFT]) within 7 days of a clinic visit. |
Within 7 days of the index rheumatology clinic visit
|
Collaborateurs et enquêteurs
Collaborateurs
Dates d'enregistrement des études
Dates principales de l'étude
Début de l'étude (Estimé)
Achèvement primaire (Estimé)
Achèvement de l'étude (Estimé)
Dates d'inscription aux études
Première soumission
Première soumission répondant aux critères de contrôle qualité
Première publication (Réel)
Mises à jour des dossiers d'étude
Dernière mise à jour publiée (Réel)
Dernière mise à jour soumise répondant aux critères de contrôle qualité
Dernière vérification
Plus d'information
Termes liés à cette étude
Mots clés
Termes MeSH pertinents supplémentaires
Autres numéros d'identification d'étude
- QIE 2024-10245
Plan pour les données individuelles des participants (IPD)
Prévoyez-vous de partager les données individuelles des participants (DPI) ?
Description du régime IPD
IDP will not be shared because this study is a quality-improvement, workflow-embedded project that uses routine clinical data obtained through participating practices' EHR systems. Data use is restricted under site agreements, HIPAA requirements, and the terms of the QIE grant, which allow only aggregated, de-identified reporting and do not permit external sharing of IPD.
Informations sur les médicaments et les dispositifs, documents d'étude
Étudie un produit pharmaceutique réglementé par la FDA américaine
Étudie un produit d'appareil réglementé par la FDA américaine
Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .